Physician profile
Jeffrey Helfenstein
NPI 1578572327
$14,132.38
in general payments reported to CMS, 2019-2025
51 companies · $1,512 in 2025
The $1,512 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,511 · 2020: $1,405 · 2021: $2,714 · 2022: $1,758 · 2023: $2,154 · 2024: $2,079 · 2025: $1,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,744.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,074.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,048.73 | 2019-2025 | Farxiga, Brilinta, Breztri |
| Novo Nordisk INC | $917.18 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $873.78 | 2020-2025 | |
| Amgen INC. | $858.69 | 2019-2025 | Repatha, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $772.68 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $640.00 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $594.85 | 2021-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $570.32 | 2021-2024 | Nexletol |
| Edwards Lifesciences Corporation | $501.66 | 2020-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amarin Pharma, INC. | $496.88 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $453.67 | 2019-2025 | Evkeeza, Dupixent, Praluent |
| Abbvie INC. | $355.06 | 2020-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $339.10 | 2019-2023 | Lifevest |
| Sanofi-Aventis U.S. LLC | $319.49 | 2019-2023 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Helfenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.